Fundraising Fox
Cerium Pharmaceuticals
Gaithersburg, US · Founded 2012 · Delaware corporation · 2 known investors
Find your way into Cerium Pharmaceuticals
Sign up to see every warm intro you have to Cerium Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cerium Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cerium Pharmaceuticals develops and commercializes medicines for rare or "orphan" diseases, including kidney disease. The company operates in the biopharmaceutical industry with a focus on the rare disease community.
Founders & leadership
Cerium Pharmaceuticals was founded in 2012 by Gregg Lapointe, Robert J. Rubin, and Nancy Klett.
RJ
Robert J. RubinCo-Founder & Interim CMO
NK
Nancy KlettCo-Founder & Chief Operating OfficerShe has held roles in human resources and project management, with experience in employee relations, workforce planning, training and development, and compensation and benefits administration.
ŞB
Şemsi Burak DerkuntChief Scientific OfficerŞemsi Burak Derkunt previously worked as a scientist focused on DNA repair and rare genetic diseases including Fanconi Anemia and Xeroderma Pigmentosum. He is Chief Scientific Officer of Cerium Pharmaceuticals, a biopharmaceutical company developing treatments for rare diseases.
PC
Peter CollumNamed on SEC filing
SE
Steve EskenaziNamed on SEC filing
TD
Tom DePasqualeNamed on SEC filing
Board
JG
Investors · 2
Also in the syndicate · 1
Alexandria Biotech, LLClead
Funding
SEC filings, press & company announcements$13.8M disclosed across 4 of 5 rounds · 2016–2026
- Undisclosed amountSeries BJan 2020
Alexandria Biotech, LLC (lead)
Source ↗
▶$750KraisedAug 2026 · 4 investors · PharmaceuticalsRule 506(b)
▶$750KraisedAug 2026 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregg A. LapointeExecutive Officer, Director
- Peter CollumDirector
- Steve EskenaziDirector
- Robert RubinDirector
- Tom DePasqualeDirector
- James GaleDirector
- Offering amount
- $2.5M
- Amount sold
- $750K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.9MraisedJul 2021 · 5 investors · BiotechnologyRule 506(b)
▶$8.9MraisedJul 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James GaleDirector
- Gregg LapointeExecutive Officer, Director
- Nancy KlettExecutive Officer
- Thomas A DePasqualeDirector
- Offering amount
- $10.1M
- Amount sold
- $8.9M
- Minimum investment
- $25K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedMay 2021 · 9 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMay 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregg LapointeExecutive Officer, Director
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- Minimum investment
- $25K
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedJun 2016 · 9 investors · BiotechnologyRule 506(c)
▶$2.3MraisedJun 2016 · 9 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Gregg LapointeExecutive Officer, Director
- Offering amount
- $7.3M
- Amount sold
- $2.3M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Collegium PharmaceuticalCollegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
CatalentCatalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.
InvenInven provides AI-powered workflows for investment and consulting firms to automatically generate company materials such as market maps, financial profiles, and competitive landscapes from structured data. The platform serves management consulting firms and investment professionals who need to produce analyst-ready documents and decks at scale.
Companies working in the same space as Cerium Pharmaceuticals.
In the news
Frequently asked questions
- What does Cerium Pharmaceuticals do?
- Cerium Pharmaceuticals develops and commercializes medicines for rare or "orphan" diseases, including kidney disease. The company operates in the biopharmaceutical industry with a focus on the rare disease community.
- Who founded Cerium Pharmaceuticals?
- Cerium Pharmaceuticals was founded by Gregg Lapointe, Robert J. Rubin, Nancy Klett in 2012.
- Who are Cerium Pharmaceuticals's investors?
- Cerium Pharmaceuticals's investors include Signet Healthcare Partners.
- How much funding has Cerium Pharmaceuticals raised?
- Cerium Pharmaceuticals has disclosed $13.8M raised across 4 of its 5 known rounds.
- Where is Cerium Pharmaceuticals headquartered?
- Cerium Pharmaceuticals is headquartered in Gaithersburg, US.